For the quarter ending 2025-09-30, IMRX made $15,796,537 in revenue. -$14,964,875 in net income. Net profit margin of -94.74%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 10,867,983 | 10,454,160 | ||
| General and administrative | 4,505,406 | 4,296,417 | ||
| Amortization of intangible asset | 7,317 | 7,317 | ||
| Total operating expenses | 15,380,706 | 14,757,894 | ||
| Loss from operations | -15,380,706 | -14,757,894 | ||
| Interest income | 415,831 | 324,013 | ||
| Other income, net | 0 | 0 | ||
| Net loss | -14,964,875 | -14,433,881 | ||
| Unrealized loss from marketable securities | 0 | 0 | ||
| Comprehensive loss | -14,964,875 | -14,433,881 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.38 | -0.4 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.38 | -0.4 | ||
| Weighted-average common shares outstanding, basic (in shares) | 39,670,095 | 35,985,878 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 39,670,095 | 35,985,878 | ||
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)